公开(公告)号：US12202894B2

公开(公告)日：2025-01-21

申请号：US16981367

申请日：2019-03-19

Applicant: Wuxi Biologics Ireland Limited

Inventor： Siwei Nie ,  Yong Zheng ,  Jing Li

IPC: C07K16/00 ,  A61K39/395 ,  A61K39/40 ,  C07H21/04 ,  C07K16/28 ,  C12N1/20 ,  C12N5/00 ,  C12P21/04 ,  C12P21/06 ,  C12P21/08 ,  G01N33/68

Abstract: The present disclosure provides anti-TIM-3 antibodies or antigen-binding fragments thereof, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.

公开(公告)号：US12186392B2

公开(公告)日：2025-01-07

申请号：US16679483

申请日：2019-11-11

Applicant: Ono Pharmaceutical Co., Ltd. ,  HOFFMANN-LA ROCHE INC.

Inventor： Christian Klein ,  Toshio Yoshizawa ,  Tomoko Yasuhiro

IPC: A61K39/395 ,  A61K31/522 ,  A61K39/40 ,  A61K45/06 ,  C07K16/28 ,  A61K39/00 ,  C07K16/00

Abstract: The present invention is directed to the combination therapy of an anti-CD20 antibody with a BTK inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with a type I anti-CD20 antibody or an afucosylated humanized B-Ly1 antibody and a BTK inhibitor.

公开(公告)号：US12152068B2

公开(公告)日：2024-11-26

申请号：US17569377

申请日：2022-01-05

Applicant: TRELLIS BIOSCIENCE, LLC

Inventor： Lawrence M. Kauvar ,  Stefan Ryser ,  Angeles Estelles ,  Reyna J. Simon ,  Lauren Opremcak Bakaletz ,  Steven David Goodman

IPC: C07K16/12 ,  A61K35/12 ,  A61K39/00 ,  A61K39/40 ,  A61K45/06 ,  A61K49/00 ,  C07K14/31 ,  C12N15/86 ,  C12Q1/18 ,  G01N33/566 ,  G01N33/569

Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human B lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.

公开(公告)号：US20240344102A1

公开(公告)日：2024-10-17

申请号：US18431564

申请日：2024-02-02

Applicant: Merus N.V.

Inventor： Cornelis Adriaan DE KRUIF ,  Linda Johanna Aleida Hendriks ,  Ton Logtenberg

IPC: C12P21/00 ,  A61K39/395 ,  A61K39/40 ,  C07K16/12 ,  C07K16/18 ,  C07K16/26 ,  C07K16/28 ,  C07K16/36 ,  C07K16/46 ,  A61K39/00

CPC classification number: C12P21/005 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/40 ,  C07K16/12 ,  C07K16/1278 ,  C07K16/1282 ,  C07K16/18 ,  C07K16/26 ,  C07K16/28 ,  C07K16/2809 ,  C07K16/283 ,  C07K16/2866 ,  C07K16/2896 ,  C07K16/36 ,  C07K16/468 ,  A61K2039/507 ,  C07K2317/14 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/56 ,  C07K2317/94

Abstract: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.

公开(公告)号：US12116409B2

公开(公告)日：2024-10-15

申请号：US17408113

申请日：2021-08-20

Applicant: Redwood Bioscience, Inc.

Inventor： David Rabuka ,  Robert George Edward Holgate ,  Francis Joseph Carr

IPC: C07K16/00 ,  A61K39/395 ,  A61K39/40 ,  C07K16/28 ,  C07K17/02 ,  C07K17/08 ,  C07K17/10 ,  C12N9/16 ,  C12P21/08

CPC classification number: C07K16/2803 ,  C07K16/2851 ,  C07K17/02 ,  C07K17/08 ,  C07K17/10 ,  C12N9/16 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  C12Y301/06

Abstract: The present disclosure provides antibodies specific for an epitope present on CD22. The antibodies are useful in various treatment, diagnostic, and monitoring applications, which are also provided.

公开(公告)号：US12065485B2

公开(公告)日：2024-08-20

申请号：US17508692

申请日：2021-10-22

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Gabriel Nunez ,  Jon Oscherwitz ,  Kemp Cease ,  Yumi Nakamura ,  Tyler Nygaard

IPC: C07K16/12 ,  A61K31/05 ,  A61K31/18 ,  A61K31/192 ,  A61K31/196 ,  A61K31/235 ,  A61K31/277 ,  A61K31/366 ,  A61K31/37 ,  A61K31/47 ,  A61K31/713 ,  A61K39/00 ,  A61K39/085 ,  A61K39/40 ,  A61K45/06 ,  C12N15/113

CPC classification number: C07K16/1271 ,  A61K31/05 ,  A61K31/18 ,  A61K31/192 ,  A61K31/196 ,  A61K31/235 ,  A61K31/277 ,  A61K31/366 ,  A61K31/37 ,  A61K31/47 ,  A61K31/713 ,  A61K39/085 ,  A61K39/40 ,  A61K45/06 ,  C12N15/113 ,  A61K2039/505 ,  A61K2039/575 ,  C07K2317/34 ,  C07K2317/76 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/31

Abstract: Materials and methods are provided for treatment and/or prevention of Staphylococcal diseases and disorders such as infection and dermal inflammation.

公开(公告)号：US12024556B2

公开(公告)日：2024-07-02

申请号：US16689593

申请日：2019-11-20

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Anna Zumsteg ,  Christos Kyratsous ,  Brinda Prasad ,  Alida Coppi

IPC: C07K16/12 ,  A61K39/00 ,  A61K39/40 ,  A61K45/06 ,  A61P31/04

CPC classification number: C07K16/1271 ,  A61K39/40 ,  A61K45/06 ,  A61P31/04 ,  A61K2039/505 ,  A61K2039/572 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/92 ,  C07K2317/94

Abstract: Speciated antibodies or antigen-binding fragments that bind staphylococcal antigens are provided, where the antibodies and antigen-binding fragments have attenuated Fc binding to Protein A or homologous protein. Compositions comprising the antibodies and methods of use are also provided. The antibodies and compositions are useful for treating staphylococcal infection, reducing serum or kidney bacterial titers, and treating symptoms associated with staphylococcal infection. The antibodies may also prevent the severity and/or duration of the primary disease.

公开(公告)号：US11926859B2

公开(公告)日：2024-03-12

申请号：US18318507

申请日：2023-05-16

Applicant: Merus N.V.

Inventor： Cornelis Adriaan De Kruif ,  Linda Johanna Aleida Hendriks ,  Ton Logtenberg

IPC: C12N15/00 ,  A61K39/395 ,  A61K39/40 ,  C07K16/12 ,  C07K16/18 ,  C07K16/26 ,  C07K16/28 ,  C07K16/36 ,  C07K16/46 ,  C12P21/00 ,  A61K39/00

CPC classification number: C12P21/005 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/40 ,  C07K16/12 ,  C07K16/1278 ,  C07K16/1282 ,  C07K16/18 ,  C07K16/26 ,  C07K16/28 ,  C07K16/2809 ,  C07K16/283 ,  C07K16/2866 ,  C07K16/2896 ,  C07K16/36 ,  C07K16/468 ,  A61K2039/507 ,  C07K2317/14 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/56 ,  C07K2317/94

Abstract: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.

公开(公告)号：US11730765B2

公开(公告)日：2023-08-22

申请号：US16332939

申请日：2017-09-13

Applicant: NORTH CAROLINA STATE UNIVERSITY

Inventor： Zhen Gu ,  Chao Wang

IPC: A61K39/395 ,  A61K35/19 ,  A61K47/68 ,  A61K47/69 ,  A61K45/06 ,  A61K39/40 ,  A61P35/00 ,  A61P9/10 ,  C12N5/078 ,  C07K16/28 ,  A61P35/04 ,  A61K47/10 ,  A61K39/00

CPC classification number: A61K35/19 ,  A61K39/3955 ,  A61K39/40 ,  A61K45/06 ,  A61K47/10 ,  A61K47/6851 ,  A61K47/69 ,  A61K47/6901 ,  A61P9/10 ,  A61P35/00 ,  A61P35/04 ,  C07K16/2818 ,  C07K16/2827 ,  C12N5/0644 ,  A61K2039/505

Abstract: The present disclosure provides compositions and methods for targeted delivery of therapeutic agents. The present disclosure further provides methods for treating or preventing the metastasis or recurrence of a cancer using platelets loaded with a therapeutic agent (for example, an immunotherapeutic agent).

公开(公告)号：US20230235030A1

公开(公告)日：2023-07-27

申请号：US18168824

申请日：2023-02-14

Applicant: Research Institute at Nationwide Children's Hospital

Inventor： Steven D. Goodman ,  Lauren O. Bakaletz

IPC: C07K16/12 ,  A01N37/46 ,  A61K39/02 ,  A61K39/395 ,  A61K39/40 ,  A61K45/06 ,  C07K16/40 ,  G01N33/569 ,  G01N33/68

CPC classification number: C07K16/1242 ,  A01N37/46 ,  A61K39/0208 ,  A61K39/39541 ,  A61K39/40 ,  A61K45/06 ,  C07K16/12 ,  C07K16/1232 ,  C07K16/40 ,  G01N33/56911 ,  G01N33/6854 ,  G01N33/6893 ,  G01N2800/24 ,  A61K2039/505

Abstract: This disclosure provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system and/or traditional antibiotics.